Pharma Archive - IOI Oleo GmbH

Trust and transparency – IMWITOR® 742 now with CEP

Robert Radsziwill2024-07-12T12:51:38+02:008. July 2024|Pharma|

Product lifecycle management (PLM) for pharmaceuticals ties up considerable capacities in the quality and regulatory departments over the entire lifecycle of the marketing authorisation. Efficient management of information relevant for the authorisation of newly developed, reformulated and generic medicinal products is therefore a significant success factor. In particular, change notifications for the active ingredients and excipients used can cause unforeseeable follow-up costs that are difficult to offset against the most competitive material prices.

Our debut as an exhibitor at CPHI China

Hendrik Wöhlk2024-06-03T14:11:12+02:0024. May 2024|Pharma|

In recent years, we have strategically strengthened our presence in the future-oriented Asian market: we have entered into new distribution partnerships and participated in numerous trade fairs. Together with our Chinese partner Beijing Fengli, we are now exhibiting at CPHI 2024 in Shanghai, emphasising our commitment to this dynamic and exciting region. Four experts from the Pharma business unit will be presenting IOI Oleo GmbH and our high-quality and proven portfolio. First and foremost, our highlights IMWITOR® 742 and MIGLYOL® 812 N Excipient, for which we recently completed the Chinese Pharmacopoeia (ChP) registration.

Core competence innovation: The R&D department of IOI Oleo GmbH

Tanja Freichel2024-04-12T12:49:46+02:001. April 2024|Company, General, Nutrition, Personal Care, Pharma, Technical Applications|

IOI Oleo GmbH is known for its high-quality oleochemical specialties and is regarded as a benchmark in many areas. To achieve and maintain this status, continuous work on existing products and innovations is required, as market requirements are changing rapidly. For this reason, we have built up a 14-strong R&D team and equipped it with the latest technology in order to be able to react proactively to trends and customer requirements.

Quality & continuity – The importance of consistently high quality of excipients and raw materials

Hendrik Wöhlk2024-03-15T12:14:45+01:005. March 2024|Pharma, Trade Fairs|

We warmly invite you to visit our booth 29 in the exhibition area of the Austria Center Vienna from March 18 to 21, 2024 and talk directly to our team of experts from R&D, Regulatory and Galenics.

Regulatory innovations – Milestones for the Chinese market – IMWITOR® 742, MIGYLOL® 810 N & MIGLYOL® 812 N

Robert Radsziwill2024-03-13T09:04:36+01:0030. January 2024|Pharma|

The filing of two further dossiers with the Chinese NMPA* represents an outstanding milestone for customers in the Chinese market. From now on, manufacturers and exporters of finished pharmaceutical products can refer to these dossiers in their application documents. Our Regulatory Affairs department will issue your "Letter of Access" on request.

CEP 2.0 completely new? Effects on the quality and layout of the certificate

Silke Möschter2023-12-14T12:54:27+01:008. December 2023|Pharma|

The high quality that we strive for in our portfolio is also reflected in our service. One aspect of this service is to make the usage of our excipients as simple and safe as possible; hence, we have selected products certified by the "European Directorate for the Quality of Medicines & HealthCare" (EDQM). The recent renewal of the certification system brings with it a number of improvements and changes.

Polymorphism in Lipids: Influence and Control in Pharmaceutical Applications

Tanja Freichel2023-10-20T11:57:27+02:0020. October 2023|Pharma|

Polymorphism is a fundamental phenomenon observed in lipid materials, encompassing a diverse group of biomolecules such as fats, oils, and phospholipids. This phenomenon refers to the ability of lipids to exist in multiple structurally distinct states of crystallinity. Polymorphism in lipid materials has significant implications, e.g. in pharmaceutical and industrial applications. Controlling lipid polymorphism can be of paramount importance in the development of lipid-based drug delivery systems.

Meet our experts at the trade fairs CPHI and AAPS

Hendrik Wöhlk2023-09-29T13:22:35+02:0025. September 2023|Pharma, Trade Fairs|

This year again, our team of experts from the Pharma business unit is once again participating in two of the most important trade fairs in the pharmaceutical industry: "CPhI" in Barcelona and "AAPS PharmSci 360" in Orlando. We use these stages to present ourselves in terms of sustainability, innovation and quality. Take the opportunity, make an appointment and meet our concentrated expertise on site.

Sensorially appealing, sustainable and regulatory compliant formulation ensures the success of topical applications

Janine Harnik2023-08-07T14:12:42+02:007. August 2023|Pharma|

The topical therapy approach is the first choice for skin diseases. However, in order to ensure the intended therapeutic success, the patient’s cooperation is indispensable - especially in the case of chronic diseases. A pleasant skin feeling is the prerequisite for enabling the patient to use creams or ointments in compliance with the prescription. The combination of uncompromisingly high quality and pleasant skin feeling is therefore of decisive importance for the Pharma business unit of IOI Oleo GmbH.

Peroxide value as a further indicator of the shelf life of lipid excipients

Robert Radsziwill2023-06-15T10:56:46+02:0010. May 2023|Pharma|

IOI Oleo GmbH enjoys an excellent reputation worldwide as a manufacturer of high-quality, lipid-based additives. In order to ensure that we maintain our standards for the highest quality and to comply with the guideline values of national and international pharmacopoeias, we attach great importance to the selection of the raw materials and suppliers we use as well as state-of-the-art production processes at our locations in Germany. In this context, the peroxide value (PV) can be used as a key indicator of the rancidity of lipids and is used by pharmaceutical companies as an indicator of the quality of their excipients.

12 Next